Drugs / rAAV9.CMV.hNAGLU
rAAV9.CMV.hNAGLU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03315182 | Oct 2017 → Apr 2022 | mucopolysaccharidosis type 3B | Abeona Therapeutics, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV9.CMV.hNAGLU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315182 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated virus serotype 9 carrying the human NAGLU gene” NCT03315182 ↗ |
| Route | Intravenous | “injected intravenously through a peripheral limb vein” NCT03315182 ↗ |